5432752025-07-012025-09-305432752025-09-305432752025-03-315432752025-04-012025-09-305432752025-07-012025-09-30in-capmkt:OtherExpenses1Member5432752025-04-012025-09-30in-capmkt:OtherExpenses1Member5432752025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15432752025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25432752025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15432752025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25432752025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15432752025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss25432752025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15432752025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss25432752025-07-012025-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543275ANURASNOTLISTEDINE930P01018ANUPAM RASAYAN INDIA LIMITEDMain BoardEquity2025-04-012026-03-312025-10-172025-10-14INRMillionsQuarterlySecond quarterSingle segmentManufacturing of Industrial Chemicals2025-10-1709:02:002025-10-1709:38:00trueCash Flow IndirectDeclaration of unmodified opinion2025-07-012025-09-30UnauditedConsolidated73139800007792000073919000004253510000-19580000509270000173740000359760000320690000103915000066365400007553600000755360000144220000396200001838400000571520000000057152000031700005746900004439300001275800004468600001278300001138480000103.933.93003.933.931. The above Consolidated Financial results for the quarter and six months ended September 30, 2025 have been prepared by the Company in accordance with Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended and were reviewed by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on October 17, 2025. <BR> 2. Based on the management approach as defined in Ind AS 108 Operating Segments the Chief Operating Decision Maker CODM evaluates the companys performance and allocates resources based on an analysis of various performance indicators of business segments in which the company operates. The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment. Hence disclosure of segment wise information is not required and accordingly not provided. <BR> 3. The Board of Directors of the Company at its meeting held on July 15, 2025 has approved the allotment of 3914886 fully paidup equity shares at an issue price of INR 945.11 per share comprising face value of INR 10 per share and premium of INR 935.11 per share on preferential allotment basis upon conversion of equal number of warrants after receipt of 75 percent amount of the issue prize of Rs. 2775 million. Out of total amount of INR 2775 million received amount of INR 2768.98 have been utilised for the repayment of Loans and General Corporate purposes upto September 30 2025 as per the objects in the offer document. <BR> 4. The Company has investment in the following subsidiary companies and an associate company as on September 30, 2025 and accordingly consolidated financial results for the quarter and half year ended September 30, 2025 includes following entities. <BR> Name of the Subsidiary Nature of relationship <BR> a. Jainam Intermediates Private Limited, Wholly owned subsidiary <BR> b. Tanfac Industries Limited, Subsidiary Company over which the Company exercises effective control <BR> c. ARIL Transmodal Logistic Private Limited, Wholly owned subsidiary <BR> d. ARIL Fluorospeciality Private Limited, Wholly owned subsidiary <BR> e. Anupam Japan GK, Wholly owned subsidiary <BR> f. Anupam Europe AG, Wholly owned subsidiary <BR> g. Anupam USA LLC, Wholly owned subsidiary <BR> h. Anupam General Trading FZE, Wholly owned subsidiary <BR> i. Tangent Science Private Limited, An associate Company of wholly owned subsidiary of the Company <BR> 5. The figures of the previous period have been regrouped rearranged and or recasted wherever considered necessary.2025-04-012025-09-30UnauditedConsolidated121722500001270400001229929000078655200000-683760000377050000716400000627510000201270000010915420000138387000001383870000261950000658200003277700000105610000000001056100000-502000010510800007843000002718000007790300002720500001138480000107.037.03007.037.03Other Expenses1039150000Other Expenses2012700000227607300005796300000123205000022915000000015200000014130000011543400001310840000022413000002835370000014915990000721700006199930000413065000024038000016280000752000010666930000123300002549510000281447600000056498460000113848000030834400000319728800002518220000344911000002486700000000248670000151800001189470000011929200002646240000114529600004230000068099700006852270000291580000185968100005395200001642500006054000019361120000002200736000056498460000728010000-402600000119509000008280700000029600000125413000000062751000002390000000-5074000014600000180000-22700000000041812700005565140000000195760000-200700005349310000000000004800000206458000013889900001380000000000000000000000014600000-482300000-2531630000003917000000000-1190400001825420000-1848600001520000006813600000273630000018251000030001900000300019000011304600004130650000Gain/(loss) on remeasurements of the defined benefits plan13080000Income tax (expense)/income on remeasurements of the defined benefits plan-45400008540000Gain/(loss) on remeasurements of the defined benefits plan-4550000Income tax (expense)/income on remeasurements of the defined benefits plan1630000-292000000Effective portion of gain/(loss) on hedging instruments in a cash flow hedge-7000000Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge1630000-5370000Effective portion of gain/(loss) on hedging instruments in a cash flow hedge-2100000Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge0-2100000003170000-5020000UnauditedtrueNatvarlal Vepari & Co.true2027-05-31